The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients Source: Eur Respir J 2014; 44: 527-529 Year: 2014
Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007
The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Effects of Omalizumab treatment on nasal symptoms (SNOT score) in patients treated for severe asthma. Source: International Congress 2017 – Asthma management Year: 2017
Tolerance to the protective effect of salmeterol on allergen challenge in mild untreated asthmatics and in moderate asthmatics on inhaled corticosteroid treatment Source: Eur Respir J 2001; 18: Suppl. 33, 103s Year: 2001
The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005
Residual reversibility in COPD subjects treated by long acting bronchodilatators Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018
Additive effects of montelukast in salmeterol treated moderate persistent asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 385s Year: 2002
Retrospective review of studies shows that patients receiving salmeterol plus ICS have fewer serious asthma exacerbations vs patients on ICS alone, regardless of ethnic origin Source: Eur Respir J 2005; 26: Suppl. 49, 429s Year: 2005
The oral corticosteroid sparing effect of omalizumab in patients with severe chronic asthma: Is there a difference when you become 12 years old? Source: Annual Congress 2011 - Treating childhood asthma Year: 2011
Three month treatment with formoterol in mild asthma: efficacy and side effects Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Improvement of control and quality of life in severe allergic asthmatics patients treated with omalizumab Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Montelukast and steroid effects on airway function compared with steroid alone and placebo: a single blind, controlled study in asthmatic school children Source: Eur Respir J 2003; 22: Suppl. 45, 132s Year: 2003
The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002
10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018
Reduction in percent of days with asthma symptoms and activity limitation in young asthmatic children treated with Montelukast Source: Eur Respir J 2001; 18: Suppl. 33, 290s Year: 2001
Patient characteristics that can predict response to omalizumab an (anti-IgE antibody) for achieving better control of asthmatic patients Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Mild asthmatic patients consistently respond to natural, low dose, allergen challenge in an EEC Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011